---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095512"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2026-08-13T12:50:09+00:00"
generated_at: "2026-08-13T12:55:06.901692+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dogwood Q2 net loss $11.5M; Halneuron Phase 2b on track, 217 patients enrolled

## Summary
- Net loss $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025; includes $6.7M non-cash IPR&D impairment.
- Cash $9.6M provides runway through Q4 2026 Phase 2b readout; R&D $3.2M, G&A $1.6M.
- Halneuron Phase 2b CINP trial: 217 patients enrolled, top-line results expected fall 2026; 12-week extension study started.
- SP16 granted FDA IND approval; NCI-funded study at UVA to start H2 2026.
- Appointed Iain Dukes (OrbiMed) as Scientific Advisory Board Chair; legacy antiviral partnership worth up to $100M.

## SEC filing metadata
- accession: 0001104659-26-095512
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2026-08-13T12:50:09+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/0001104659-26-095512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095512
- JSON: https://secwatch.observer/filing/0001104659-26-095512.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.